Effectiveness of the Telemonitoring Program for Patients With Chronic Obstructive Pulmonary Disease (COPD)

The primary objective of the intervention is to optimize disease management and reduce the need for hospital-based healthcare resources.

• Personalized Patient Monitoring: The telemonitoring system enables continuous, individualized follow-up, supporting proactive disease management and timely clinical decision-making.
• Early Detection of Exacerbations: The HCAlert system continuously monitors physiological parameters, including heart rate, oxygen saturation (SpO₂), and blood pressure, and uses a triage algorithm to generate clinical alerts. This remote monitoring approach facilitates the early identification of clinical deterioration, allowing timely intervention before the patient's condition worsens, thereby potentially improving clinical outcomes.
• Reduction in Healthcare Resource Utilization: Early clinical intervention is expected to reduce the rate of COPD-related hospitalizations, the number of COPD-related hospital days, and the frequency of COPD exacerbations. These improvements may translate into reduced healthcare resource utilization and lower healthcare costs.
• Improved Quality of Life: By enabling patients to receive continuous monitoring and clinical support while remaining at home, telemonitoring may improve overall quality of life, increase patient reassurance, and promote better adherence to prescribed treatment plans.

Inclusion criteria

• Male or female aged 18 years or older.
• Patient with a confirmed diagnosis of chronic obstructive pulmonary disease (COPD), classified according to the GOLD ABE classification, who has experienced at least one COPD exacerbation within the previous 12 months.
• Able and willing to provide written informed consent.
• Able to comply with the telemonitoring procedures, including:
• Performing physiological measurements on a regular basis;
• Completing the required questionnaires.
• Covered by a valid health insurance or social security scheme.

Exclusion criteria

• Receiving long-term oxygen therapy (LTOT) or non-invasive ventilation (NIV), regardless of the duration since prescription.
• Presence of severe, unstable comorbidities that may interfere with the study outcomes, including but not limited to:
• Decompensated heart failure;
• Chronic kidney disease;
• Asthma;
• Other restrictive pulmonary diseases;
• Psychotic mental disorders.
• Participation in another interventional clinical study within the month preceding enrollment or during the study period.
• Unavailable for follow-up or planning to relocate before completion of study participation.
• Protected populations, including:
• Pregnant or breastfeeding women, or women planning to become pregnant during the study period. For women of childbearing potential not using effective contraception, pregnancy will be ruled out by a urine or blood human chorionic gonadotropin (hCG) test before enrollment.
• Individuals deprived of liberty by judicial or administrative decision, or individuals under legal protection measures.